Document is current

Any future updates will be listed below

Jorveza® — erste zugelassene Therapie bei eosinophiler Ösophagitis

Crossref DOI link: https://doi.org/10.1007/s15007-019-1896-8

Published Online: 2019-07-30

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark